Central Pennsylvania Transplant Foundation Incorporated

Programs: 1. Astellas 7163-cl-0108: "a phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of askp1240 in de novo kidney transplant recipients-; principal investigator: harold yang md phd; december 2012-may 2017. Study completed. 2. Bristol-myers squibb protocol im103-116: "evaluation of the benefits and risks in maintenance renal transplant recipients following conversion to nulojix (belatacept)-based immunosuppression-; principal investigator: harold yang md phd; june 2013-present. Study active. Enrollment closed. 3. Bristol-myers squibb protocol im103-177: "evaluation of acute rejection rates in de novo renal transplant recipients following thymoglobulin induction, cni-free, nulojix (belatacept)-based immunosuppression-; principal investigator: harold yang md phd; april 2014-present. Study active. Enrollment closed. 4. Novartis protocol crad001a2433: a 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs. Mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- advancing renal transplant efficacy and safety outcomes with an everolimus-based regimen (transform); principal investigator: mary waybill md; april 2014- present. Study closed. Awaiting closeout. 5. Prolong protocol sgtp-002: "a randomized, placebo-controlled, prospective, double-blind, multicenter phase 2/3 study of the efficacy and safety of sanguinate(trademark) for reduction of delayed graft function in recipients of a donation after brain death kidney transplant-; october 2015-may 2017. Study completed. 6. Alberta transplant applied genomics centre:diagnostic and therapeutic applications of microaarays in organ transplantation and native organ diseases: using microarrays to assess transplant biopsies: the future standard of care (intercomex: the intercom extension study); september 2015-present. Study closed. Awaiting final results. 7. Astellas7163-cl-3201:"a phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of bleselumab in preventing the recurrence of focal segmental glomeruloscerosis in de novo kidney transplant recipients-; february 2017-present. Study active. Enrollment open.